Research Papers:
Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis
Metrics: PDF 1563 views | HTML 4063 views | ?
Abstract
Cong Xu1,2,*, Hua Li1,*, Miao Yin1, Tao Yang1, Liguo An1 and Guiwen Yang1
1Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal University, Jinan 250014, China
2College of Pharmacy, Binzhou Medical University, Yantai 264003, China
*These authors contributed equally to this work
Correspondence to:
Guiwen Yang, email: [email protected]
Liguo An, email: [email protected]
Keywords: osteopontin, TLR4, proliferation, metastasis, ovarian cancer
Received: July 02, 2017 Accepted: September 23, 2017 Published: October 12, 2017
ABSTRACT
Tumor cell proliferation and metastasis are critical for tumor progression and lead to death of cancer patients. TLR4 is a member of the toll-like receptor (TLR) family, which promotes tumor growth, metastasis and immune escape. Osteopontin (OPN), a phosphorylated glycoprotein extensively expressed in multiple cell-types, plays important roles in tumorigenesis, metastasis and infiltration, and participates in signal transduction of innate immunity. However, it is unclear whether TLR4 has any relationship with OPN. The current study investigated the role of TLR4 and OPN in tumor proliferation and metastasis, and the potential effect of TLR4 signaling on OPN using the human ovarian cancer cell line HO-8910PM. High expression levels of TLR4 and OPN were detected in HO-8910PM cells, which promoted the proliferation, migration and invasion of tumor cells. Lipopolysaccharide (LPS) induced activation of TLR4 up-regulated OPN, increasing the malignant phenotype of cells. RNAi-mediated knockdown of OPN reduced significantly the metastatic phenotype activated by TLR4. Taken together, our study demonstrates that OPN contributes to the ovarian cancer cell proliferation and metastasis, which is activated by TLR4 signaling pathway. It provides new insights for the mechanisms of tumor development and metastasis, and suggests targeting TLR4 and OPN as an intervention in the ovarian cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21844